Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you smell the money?????
MHTX has been to quite, watch that one to break north!
Watching CSGJ?????
EWPI .22 x .31 last .29 very low float!
Morning Edward, have a look at EWPI!
VG 1.55 (:
GLTA!!!
THRA .0085's will be gone at open!!!!
THRA news: Therma-Med, Inc. Enters Negotiations With a Major Southern Ontario Wellness Centre
2010-03-01 08:00 ET - News Release
BEVERLY HILLS, CA -- (MARKET WIRE) -- 03/01/10
is Therma-Med, Inc. (PINKSHEETS: THRA) has commenced acquisition negotiations with another established Wellness Centre in the Greater Toronto area of Southern Ontario.
The company's goals continue to focus on establishing the highest level of clinical operations support to existing wellness clinics, while continuing to move forward with key acquisitions.
The potential clinic has been providing chiropractic and related wellness procedures for over 11 years and has established a loyal patient base of over 700 patients since its inauguration in this continuously growing community.
Therma-Med, Inc. continues with their vision to add DITI (Digital Infrared Thermal Imaging) services to their clinical operations and to focus more on the opportunities to provide health care services beyond the traditional medical approaches.
This acquisition will be another move forward in the company's plan to add additional revenue streams under the Therma-Med umbrella.
They can't hold this down any longer!
Onwards and Upwards!!!!!
THRA getting on many screens!!!!
Good for a few points!!!
Start of a new trading month...now lets see the pps come up!
Hopefully these acquisitions are profitable, otherwise they would not be buying them!!!
Morning...could this be the week we hear something????
Very nice, that industry of supplements is HUGE!!!!
Looks like you have the #1 Pick!!!!
THRA...you've got the right ticket!
She'll break north from here imo!
THRA .0092 x .0099 nice volume!!!!!
JAV....bid support firming up!
So far it's not YELLOW!!!!!!
Looks like its time!
Ditto, have a great day out there!!!!!
Now that the company is at checkmark status, we should see good things come out of them!
Joan...time to go for the GOLD?
Morning...Did u manage to catch FTRSQ this morning?
BEDA and FTRSQ ripping north!!!
ALNS news>>>> Alentus Corporation Announces Insider Stock Purchase
2010-02-24 09:30 ET - News Release
LAS VEGAS, NV -- (MARKET WIRE) -- 02/24/10
Alentus Corporation (PINKSHEETS: ALNS), a web hosting, domain registrar, dedicated server, collocation, and E-Commerce hosting provider announces that Randy Reineck, currently EVP Corporate Development, recently purchased 1,100,000 shares of Alentus restricted common stock which when added to the 3,300,000 shares purchased in 2009 results in the cumulative purchase of 4,400,000 shares for a total purchase price of $176,000, an average of 4 cents per share.
Morning to you sir!
I'm seeing a down trend on that one!
MBI's results are scheduled for Tuesday, March 2, at 8:00 A.M. should be a good one imo!!!
Still waiting patiently on the sidelines!!!
Is ALNS ready to go?
Hope you took your gains and moved on to VG!!!!
Morning young lady!
Things are looking up!
Toyota Motor Corp. Cut To Neutral From Buy By Goldman Sachs
DDSS up on news: Labopharm Receives FDA Approval For OLEPTRO(TM)
2010-02-03 07:00 ET - News Release
- Second U.S. FDA Product Approval in Just Over a Year For Labopharm's CONTRAMID(R) Controlled Release Technology -
LAVAL, QC and PRINCETON, NJ, Feb. 3 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.
"OLEPTRO(TM) represents Labopharm's second CONTRAMID(R) technology-based product to receive FDA approval in just over a year," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We are excited about the opportunity for OLEPTRO(TM) and are preparing the product for launch into the $11 billion-plus U.S. antidepressant market. We are working towards finalizing a commercialization path for OLEPTRO(TM) that will maximize the value of our product in this market."
MDD is a common mental illness often characterized by a combination of social and somatic symptoms. It affects more than 14 million adults in the U.S. and is the leading cause of disability globally. OLEPTRO(TM) will offer physicians another therapeutic alternative for their MDD patients.
"There's a large body of evidence demonstrating the efficacy of trazodone in the treatment of MDD," said Dr. Stephen Stahl, Adjunct Professor of Psychiatry, University of California, San Diego School of Medicine. "Labopharm has developed a novel formulation of trazodone that effectively treats depression and provides a tolerable adverse event profile."
Labopharm is actively exploring several alternatives for the U.S. commercialization of OLEPTRO(TM). Such alternatives range from out-licensing the product to a distribution partner while retaining the right to some degree of co-promotion, through to a full co-promotion arrangement under which Labopharm would share the sales function with a partner. The Company currently expects to finalize the commercialization plan for OLEPTRO(TM) in the near term.
Labopharm expects OLEPTRO(TM) to be available for prescription in the U.S. later this year, with specific timing for its launch to be determined within the context of the final commercialization plan. The Company believes it is well advanced in its preparations for the U.S. launch of OLEPTRO(TM). The Company has completed market research with physicians and third-party payors, developed a positioning and marketing campaign for OLEPTRO(TM), and finalized product manufacturing and packaging arrangements.